Cynvenio Biosystems, Inc. and Color Genomics, Inc. have announced a partnership to offer the Color Test, a hereditary cancer panel that analyzes 30 genes including BRCA1 and BRCA2 with Concesio's ClearID Breast Cancer test, a specialized next-generation sequencing (NGS) panel that interrogates 27 genes for somatic mutations in breast cancer.
The combined Color and ClearID tests delivers a comprehensive approach for assessing hereditary breast cancer risk and monitoring patients at risk of
RelSci News & Alerts gets you:
- 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
- Competitive business intelligence through daily data updates
- Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox